Perceptive Advisors LLC lowered its position in AnaptysBio Inc (NASDAQ:ANAB) by 23.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 756,387 shares of the biotechnology company’s stock after selling 225,882 shares during the period. AnaptysBio accounts for 2.5% of Perceptive Advisors LLC’s portfolio, making the stock its 8th largest holding. Perceptive Advisors LLC’s holdings in AnaptysBio were worth $76,183,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Evercore Wealth Management LLC acquired a new stake in shares of AnaptysBio in the third quarter valued at approximately $100,000. Legal & General Group Plc increased its holdings in shares of AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of AnaptysBio in the second quarter valued at approximately $168,000. Nationwide Fund Advisors increased its holdings in shares of AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,776 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in shares of AnaptysBio in the fourth quarter valued at approximately $212,000. Institutional investors own 99.25% of the company’s stock.
A number of analysts recently weighed in on ANAB shares. SunTrust Banks raised their price target on shares of AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Robert W. Baird reissued a “buy” rating and issued a $144.00 price target (up previously from $81.00) on shares of AnaptysBio in a report on Friday, January 19th. Royal Bank of Canada raised their price target on shares of AnaptysBio to $144.00 and gave the company an “outperform” rating in a report on Friday, March 2nd. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, ValuEngine raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. AnaptysBio presently has an average rating of “Buy” and an average target price of $129.67.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.12. The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $0.89 million. AnaptysBio’s revenue for the quarter was up 9.1% on a year-over-year basis. research analysts expect that AnaptysBio Inc will post -2.3 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/03/12/perceptive-advisors-llc-has-76-18-million-stake-in-anaptysbio-inc-anab.html.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.